 Liminal BioSciences Incs NASDAQ: LMNL subsidiary Prometic Biotherapeutics Inc has agreed to sell its Rare Pediatric Disease Priority Review Voucher PRV for 105M. The FDA granted the PRV with the approval of Ryplazim plasminogen, human-tvmh for plasminogen deficiency type 1 hypoplasminogenemia. 